Shots:

• The global program includes two P-III studies assessing vadadustat (PO) vs darbepoetin alfa (inj.) in a ratio (1:1) in incident dialysis patients (Correction/Conversion) and prevalent dialysis patients (Conversion)- in ~3-923 adult patients on dialysis with anemia due to CKD
• The presentation expands on previously reported positive data showing vadadustat achieved clear and consistent results across 1EPs & 2EPs
• Vadadustat is an oral HIF-PH inhibitor designed to mimic the physiologic effect of altitude on oxygen availability and is also being evaluated in P-III PRO2TECT for anemia due to CKD in adult patients- not on dialysis. The company plans to submit NDA to the US FDA for anemia due to CKD in adult dialysis-dependent and non-dialysis dependent patients in 2021

 ­ Ref: Akebia | Image: Akebia